The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
Journal of Psychopharmacology February 25, 2022 Francis M. Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad et al. 16 citations
A single 84 mg dose of intranasal esketamine did not impair next-morning driving performance in patients with mild-to-moderate major depressive disorder or persistent depressive disorder, and same-day driving was not impaired after twice-weekly administration over three weeks. Alcohol, used as a positive control, significantly worsened driving (increased weaving by 1.83 cm), while esketamine showed no such effect. Twenty-seven patients completed on-road driving tests on a public highway. The findings suggest that esketamine, at this dose, does not compromise driving ability the morning after or on the same day of repeated use.